Skip Navigation Links
Centers for Disease Control and Prevention
CDC
CDC CDC Home Search Health Topics A-Z
Contact Help Travelers Health n i p Home NIP header

Vaccine Identification Standards Initiative
VISI Home
Background and Rationale
Process
Meetings
Draft Application Guidelines and Prototypes
Public comment and feedback

NIP:
NIP HOME
First time visitor?
About NIP
Data and Statistics
International Efforts
Links to other web sites 
bullet Glossary/ Acronyms 

NIP sub-sites:
ACIP
Flu Vaccine
Immunization Registries
Vaccines for Children Program
CASA (Clinic Assessment Program)
AFIX (Grantee Assessment)
VACMAN
 

NIP Site Search
 
For Immunization Information, call the
CDC-INFO Contact Center:
English and Spanish
800-CDC-INFO
800-232-4636
TTY
888-232-6348

Get Acrobat Reader
Get Adobe Reader
Home Health Care Professionals Homepage Partners Homepage Media Homepage Health Care Professionals
 

VISI Logo - Click to go to home page of Vaccine Identification Standards Initiative  

Vaccine

Identification

Standards

Initiative

Vaccine Abbreviations

Cover page of Elementary Treatise on Chemistry, by Lavoisier, 1789.  CLICK FOR LARGER PHOTOGRAPH.

 

ELEMENTARY  TREATISE ON  CHEMISTRY, PRESENTED IN A NEW ORDER AND ACCORDING TO  MODERN  DISCOVERIES

 

1789, Paris

(Translation by Robert Kerr, Edinburgh, 1790; Dover facsimile edition, 1965)

     The impossibility of separating the nomenclature of a science from the science itself, is owing to this, that every branch of physical science must consist of three things; the series of facts which are the objects of the science, the ideas which represent these facts, and the words by which these ideas are expressed.

     Like three impressions of the same seal, the word ought to produce the idea, and the idea to be a picture of the fact.  And, as ideas are preserved and communicated by means of words, it necessarily follows that we cannot improve the language of any science without at the same time improving the science itself; neither can we, on the other hand, improve a science, without improving the language or nomenclature which belongs to it.  . . .

     A salt, though compounded of the same three principles, may, nevertheless, by the mere difference of their proportion, be in three different states.  The nomenclature we have adopted would have been defective, had it not expressed these different states; and this we attained chiefly by changes of termination uniformly applied to the same state of the different salts.  In short, we have advanced so far, that from the name alone may be instantly found what the combustible substance is which enters into any combination . . .  .

     It may be easily supposed that it was not possible to attain all these different objects without departing, in some instances, from established custom, and adopting terms which at first sight will appear uncouth and barbarous.  But we considered that the ear is soon habituated to new words, especially when they are connected with a general and rational system.   . . .

     When we published our essay on the nomenclature of chemistry, we were reproached for having changed the language which was spoken by our masters, which they distinguished by their authority, and handed down to us.  . . .  I shall conclude this preface by transcribing, literally, some observations of the Abbé de Condillac . . .  .  "But, after all, the sciences have made progress, because philosophers have applied themselves with more attention to observe, and have communicated to their language that precision and accuracy which they have employed in their observations: In correcting their language they reason better."   --  Antoine Laurent Lavoisier

(updated 2003-Nov-12)

The following nomenclature of abbreviations for past, current, and future human vaccines are a proposed standard in order to facilitate accuracy, consistency, and convenience, and to avoid errors and ambiguity, in vaccine labeling, medical practice, record keeping, written communications, and scientific publications.

 1.  EUROPEAN PRECEDENTS
 2.  PRINCIPAL MAIN ROOT FORMAT
 3.  NAMING PRINCIPLES
            Disease/agent representation
            Intuitiveness
            Specificity
            Consistency
            Significance
 4.  NON-CONFORMING EXCEPTIONS
 5.  SPECIFIERS AS SUBSCRIPTS
            Specifier dashes
            Specifier legibility
            Subscripting alternatives
            Data entry screen display
            Omitting subscript specifiers
 6.  VECTORED VACCINES
 7.  BOLDFACING RECOMMENDED
 8.  DISTINGUISHING VACCINE FROM AGENT OR DISEASE
 9.  COMBINATION VACCINE NOTATION
10.  LISTING SEQUENCE OF COMBINATION ANTIGENS
       
     Grandfathered combinations
            New additions to existing combinations
            Multiple newly-added antigens
            New combinations
11.  SIMULTANEOUS VACCINATION NOTATION
12.  AMBIGUOUS AND ILLEGIBLE CONJUNCTIONS
13.  USER FLEXIBILITY
            Conjugate used
            Serotypes and seed strains
            Valency
            Manufacturer
14.  ORDER OF MULTIPLE SUBSCRIPTS
15.  ABBREVIATION TABLE
16.  Resource Links

These abbreviations are promulgated on the following rationale and guidelines:

  1. EUROPEAN PRECEDENTS.  To facilitate universality, the format builds upon and harmonizes as feasibly as practical with a vaccine abbreviation nomenclature (Vaccine, 2000;18:1539-1542) developed by a drafting group [PA/PH/OMCL (97) 43, R] of the European Network of Official Medicines Control Laboratories of the European Department for the Quality of Medicines of the Council of Europe.  Also adopted are some suggestions by Perry and Parish a half-century ago, despite different meanings assigned to a few shared homonymous abbreviations (Abbreviated titles for serological products, British Medical Journal, 7 July 1956;2:38-39).  

    The only unharmonized abbreviations for which the main root differs between the VISI and European proposals are for vaccines to prevent:
            a.  adenovirus (VISI = ADE Eur = ADV)
            b.  cholera (VISI = CHOo and CHOi; Eur = oraCOL and CHI, respectively)
            c.  Escherichia coli disease (VISI = ECO Eur = ECT)
            d.  Lyme disease/borreliosis (VISI = LYM Eur = BOR)
       
         e.  measles, mumps, and rubella (VISI = MMR Eur = MEA-MUM-RUB)
       
         f.  typhoid (VISI = TYD ; Eur = TYP)
      
    Also, in contrast to VISI, the European proposal has only three specifiers -- lowercase but not subscripted -- which precede the main root they modify:  "ora" (for oral), "a" (acellular), and "w" (whole cell).    [return to index at top]
      

  2. PRINCIPAL MAIN ROOT FORMAT.  In general, VISI abbreviations begin with a main root of three letters in capitals (uppercase) for each disease prevented by the vaccine (e.g.,  HAV, HBV, HIB, INF, MEA, MEN, MUM, PNU, RAB, RUBVAR,  & YEL).  Different vaccines to prevent the same disease should share the same main root.  For many purposes, no additional characters are necessary beyond the main root.   [return to index at top]  

  3. NAMING PRINCIPLES.  In deriving a main root abbreviation for a new vaccine, or selecting from among diverse abbreviations in current use for an existing vaccine, the choice should try to satisfy as many as possible of the following:  

    • Disease/agent representation.  The abbreviation should use the first three letters (first choice), or key consonants (second choice), or initial letters of multiple words (third choice) of the name of the disease or its pathogenic agent.   [return to index at top]
        

    • Intuitiveness.  The abbreviation should represent as intuitively as possible to a general audience the name of the disease or its pathogenic agent.  For example, TUB for new tuberculosis vaccines not containing Bacille Calmette-Guérin, and ANT (rather than "AVA") for anthrax vaccine.   [return to index at top]
         

    • Specificity.  The abbreviation should enhance specificity and avoid confusion for other vaccines (obsolete, existing, or anticipated) with similar names.  If possible, letters should be selected from the disease or organism name that distinguish it from similarly-named vaccines.  For example, both rabies vaccine and rotavirus vaccine have been abbreviated as "RV" or "Rv" in the literature.  To avoid ambiguity, these vaccines are abbreviated RAB and ROT to distinguish them.  "BRU" is avoided for either brucellosis or Brugia malayi vaccines; instead BRC and BRG are used, respectively.  In choosing an abbreviation for leptospirosis vaccine, LPT is selected instead of "LPS" to avoid confusion with leprosy vaccine (LPR), which has no "T".  HNT is used to abbreviate hantaan (hantavirus) vaccine, instead of "HAN", to avoid confusion with Hansen's disease (leprosy).  "MEL" is avoided for either melanoma or melioidosis vaccines; instead MLN and MLD are used, respectively.  "TYP" is avoided for either typhoid or the typhus vaccines; instead TYD, TPL, TPM, and TPS are used.  [return to index at top]
        

    • Consistency.  The abbreviation should use a common format for current or future vaccines with parallel disease or etiologic agent names.  For example, among formats in current usage to abbreviate the viral hepatitides, such as "HepX", "Hep X", "HX", and "HXV", the last is selected (e.g., HAV and HBV) and should be used for future abbreviations HCV, HDV, HEV,  and HGV  for hepatitis C, D, E, and G, respectively.  [return to index at top]
          

    • Significance.  The use of the letter "V" to represent "vaccine" or "virus" is superfluous and should be avoided in order to maximize for future use the meaning that may be conveyed by only three characters in the root abbreviation.  "V" should be accepted only in well-established abbreviations for etiologic agents or vaccines, such as for HAV, HBV, HIV, HSV, RSV, and grandfathered alternatives IPV and OPV.   [return to index at top] 

  4. NON-CONFORMING EXCEPTIONS.  Several long-established, well-recognized, and widely-accepted abbreviations which would otherwise not satisfy the format style, are incorporated on a "grandfather" basis and indicated by asterisks (*) in the table below.  The parentheses following these grandfathered abbreviations illustrate hypothetically what otherwise would have been the conforming format:  BCG (TUBBCG),  DT (DIP-TET),  DTP (DIP-PER-TET),  IG (IMG),  QF (QFE),  MMR (MEA-MUM-RUB),  Td (DIPr-TET),  and TT (TET).  In the case of polio vaccines, the abbreviations POLIPV and POLOPV are accompanied by alternatives IPV and OPV, respectively, which may be used as grandfathered equivalents.  [return to index at top]
      

  5. SPECIFIERS AS SUBSCRIPTS.  If necessary or desired to distinguish different vaccines for the same disease, subscripted specifiers are used after the capitalized main roots (e.g., DTPw, DTPa, HIBHbOC, HIBPRP-T, PNUpsPNUcn, RABHDCV,  and RABPCEC).  Subscripting follows the long tradition of chemical abbreviation, developed centuries ago by Lavoisier Portrait of Antoine Laurent Lavoisier, Guyton de Morveau Portrait of Louis Bernard Guyton de Morveau, and Berzelius Portrait of Jons Jakob Berzelius, and which is understood by schoolchildren everywhere ("H2O", "CO2").  The case used for the specifier (lowercase or CAPITALS, or mixed) should correspond to the usual style in current practice for such designations (E.g., LYMospA, RABFRhL-2, TYDAKD, TYDVi).  If no style is established, then lowercase is preferred.  If a vector also happens to be a vaccine agent with a root abbreviation of its own, then the subscripted specifier should be the vaccine's root abbreviation in caps (e.g., HIVrvVEE).  Multiple specifiers may be used in a single abbreviation to convey various kinds of information about the vaccine (see USER FLEXIBILITY below).  Examples of specifiers that may be used are:    [return to index at top]
      

    AAAspecifier

              Meaning          

    AAAa acellular; or attenuated (live)
    AAAad adsorbed
    AAAatx antitoxin
    AAAav antivenin
    AAAA , AAAB A or B, etc., serogroup, serotype, type, etc.
    AAAc central, or Central European, type or strain
    AAAcl calf lymph
    AAAcn conjugate
    AAAdna deoxyribose nucleic acid
    AAAe eastern, or European, type or strain
    AAAi inactivated (killed)
    AAAig immune globulin
    AAAim intramuscular
    AAAin intranasal
    AAAiv intravenous
    AAALPS lipopolysaccharide
    AAAmab monoclonal antibody
    AAA(AVP)
    AAA
    (GSK)
    AAA(MRK)
    AAA(WYE)
    manufacturer/distributor (e.g., Aventis Pasteur, GlaxoSmithKline, Merck, Wyeth, etc.; see standardized manufacturer abbreviations)
    AAAn northern, or North American, type or strain
    AAAo oral
    AAAps polysaccharide
    AAAr recombinant; or reduced antigen quantity for adults (relative to pediatric quantity)
    AAArna ribose nucleic acid
    AAArr rhesus reassortant
    AAAs split virion
    AAAtc tissue culture
    AAAtxd toxoid
    AAAv vector, vectored vaccine
    AAAw whole cell; or whole virion

      [return to index at top]

    • Specifier dashes.  In general, dashes or hyphens (  -  ) should be used to separate multiple specifiers conveying distinct kinds of information, such as vaccine type and valency (e.g., PNUps and PNU23 become PNUps-23).  Dashes should be omitted between multiple specifiers for similar or related details about the vaccine (e.g., recombinant vector BCG designed to prevent HIV disease: HIVrvBCG, or the protein for a conjugated vaccine: PNUcnCRM197).  In any case, dashes within specifiers may be added or omitted at the user's discretion to improve legibility and understanding (e.g., to separate numeric types contained in a combination vaccine: HPV11-16-18).    [return to index at top]  

    • Specifier legibility.  To improve legibility for reading subscripts in typeset publications, it is suggested to follow the common practice in notation of other scientific abbreviations (e.g., H2O, CO2, H2SO4, TCID50, mm3, 3 x 105, µg mL-1, Leon 12a1b type 3 Sabin poliovirus strain, etc.) by increasing the size and/or raising the level of subscripts from default settings.  Specifiers in word processing and typesetting software should be modified to maintain their size at ~80% to ~90% of the normal font size, rather than much smaller default sizes.  After formatting the specifier as a subscript, its size may be increased by changing its font size.  To avoid potential interference of subscripts with uppercase characters on the lines below, the subscript position setting may be changed to drop only ~15% to ~20% or less below the baseline, rather than a greater default drop percentage.  For example, in Microsoft Word® 2000, the command sequence after highlighting the specifier would be:  Format > Font > Subscript [check box under "Effects"] > Size [select point size 115% to 133% larger than current font size] > [Enter].  In Adobe Pagemaker®, the command sequence would be: Type > Character > Position: subscript > Options > Super/Subscript size: 90% > Subscript Position: 15% -to- 25% > OK. [return to index at top]
        

    • Subscripting alternatives.  If subscripting below the baseline of the main root abbreviation is not available, specifiers to distinguish different vaccines for the same disease simply may be entered in a smaller font size that still retains legibility, i.e., 80% to 90% of the size for the 3-letter main root (e.g., DTPwDTPaHIBHbOCHIBPRP-TMENps-ACYWPNUps-23PNUcn-7RABHDCV, and RABPCEC) (see column 2 in table).  Finally, if no text formatting is possible, as in ASCII text and database entry, then the specifiers may be typed as is, with no size or position adjustment (see column 3 in table) (e.g., DTPwDTPaHIBHbOCHIBPRP-TMENps-ACYWPNUps-23PNUcn-7RABHDCV,  and  RABPCEC).  [return to index at top]  

    • Data entry screen display.  Data entry software programs may be designed automatically for screen display of all characters after the third in the preferred subscripted and/or reduced-size format, and to format thus any printed output.  In such programs, keyboard entry of grandfathered two-letter main root abbreviations might be preceded by a space character to avoid misregistration (inadvertently as 3rd position) of the initial character of the specifier (should be 4th position) (e.g., ¯DT(AVP), ¯IG(BAY), ¯QF(CSL), ¯Td(SSV), ¯TT(SII), and ¯YF(AVP) ) .     [return to index at top]  

    • Omitting subscript specifiers.  Various possible subscript (or lowercase) specifiers may be omitted In situations where there is no ambiguity as to the vaccine which the root abbreviation identifies, such as HIB to indicate HIBcn when its forerunner HIBps vaccine is no longer in use.  The same principle would apply to the use of only the capitalized root abbreviations for PNUcn and MENcn in possible future combination vaccines (such as MEN-PNU, or  HIB-PNU) when it is anticipated only conjugated antigens would be used in such products.  Similarly, PNU5, PNU7, PNU9, and PNU11, may be used to indicate 5-, 7-, 9-, and 11-valent pneumococcal conjugate vaccines, respectively (instead of PNUcn-7, for example), when there is no contextual ambiguity with existing  (PNUps-23) or future polysaccharide vaccines (PNUps) which do not have these valencies.  Again, combination products containing inactivated poliovirus vaccine POLIPV may eliminate the specifier when there is no ambiguity with the oral polio vaccine, as in HIB-PNU-POL and DTPa-HBV-POL[return to index at top]

      

  6. VECTORED VACCINES.  Vaccines to prevent a disease (e.g., human immunodeficiency virus disease, influenza, listeriosis, or smallpox) which consist of recombinant or attenuated agents for other diseases acting as vectors or Jennerian vaccines (e.g., recombinant BCG, recombinant Listeria monocytogenes, recombinant Salmonella typhimurium, or vaccinia virus, respectively) should be assigned the root abbreviation for the disease to be prevented (e.g., HIV, INF, LIS, and SMA, respectively).  Specifiers (see below) may be appended to identify the vector or Jennerian agent used (e.g., HIVrvBCG, INFrvLISLISrvSAL, and SMAvac, respectively).   [return to index at top]

      
  7. BOLDFACING RECOMMENDED.  Vaccine abbreviations should be boldfaced to enhance recognition as a vaccine abbreviation, and to distinguish them from abbreviations for etiologic agents and disease, unless contravened by the style guidelines of the publication.    [return to index at top]   


  8. DISTINGUISHING VACCINE FROM AGENT OR DISEASE.  There are occasions when documents will need to distinguish between etiologic agents or disease names and the vaccines which prevent them.  By design, abbreviations for vaccines will often be the same as abbreviations for the associated etiologic agent (e.g., hepatitis B virus, Haemophilus influenzae type b, human immunodeficiency virus, herpes simplex virus, etc.) or disease (e.g., group A and group B streptococcal diseases, respiratory syncytial virus, etc.).  In such cases, it is suggested that at first mention in the main text of a vaccine (e.g., "hepatitis B vaccine", "Haemophilus influenzae type b vaccine", "human immunodeficiency virus vaccine", or "group B streptococcal disease vaccine"), it be followed immediately by its boldfaced abbreviation in parentheses ["(HBV)", "(HIB)", "(HIV)", or "(GBS)", respectively], and that the vaccine abbreviation be boldfaced thereafter in the document.  At the first naming of an etiologic agent or disease in the document (e.g., "hepatitis B virus", "Haemophilus influenzae type b", "human immunodeficiency virus", or "group B streptococcal disease"), a non-boldfaced abbreviation may be provided in parentheses ["(HBV)", "(Hib)", "(HIV)", or "(GBS)"] or an alternative designation established (e.g., "HB virus", "Hib disease", "HIV virus", or "GBS disease") and used thereafter.   [return to index at top] 
      

  9. COMBINATION VACCINE NOTATION.  For combination vaccines with antigens preventing two or more diseases, "hyphens" or "dashes" (-) without spaces are used to link the abbreviations of its separate components (e.g.,  DTPw-HIB-HBV, DTPa-HBV-POLHAV-HBVHIB-HBV, MEA-RUBMMR-VAR,  and  MUM-RUB) (Note: this differs from the European proposal, which used blank spaces to separate the multiple antigens comprising an individual combination vaccine.)   [return to index at top] 
      

  10. LISTING SEQUENCE OF COMBINATION ANTIGENS.  The individual vaccine antigens comprising a combination vaccine should be ordered in an abbreviation according to the following rules, arranged in descending order of precedence:  

  • Grandfathered combinations.  For existing combination vaccines whose abbreviations have been incorporated unchanged into these guidelines based on widespread use and acceptance (e.g., DTP, DTPw, DTPa), the non-alphabetical sequence in which antigens may be arranged remains unchanged.     [return to index at top]  

  • New additions to existing combinations.  When a new antigen is added to a previously-licensed combination of antigens, the abbreviation root for the new antigen should be appended after the previously-combined antigens (e.g., DTPw-HIB, DTPa-HIB, DTPa-HIB-POL, MMR-VAR), even if the new antigen appears out of alphabetical order.   [return to index at top]  

  • Multiple newly-added antigens.  When multiple new antigens are added simultaneously to an existing combination, the new antigens should be listed in alphabetical order according to the official, spelled-out, full generic name of the vaccines being combined (e.g., DTPa-HIB-HBV, DTPa-HIB-HBV-POL).  (Some abbreviations listed in the table below for future combination vaccines may need to be re-ordered according to the actual chronology in which their components become combined, according to the prior rule.)   [return to index at top]   

  • New combinations.  When a new combination vaccine is developed from multiple antigens not previously together in a licensed product, the abbreviation roots should be listed in alphabetical order according to the official, spelled-out, full generic names of the component vaccines (e.g., HAV-HBV, HIB-HBV, HIB-MEN, HIB-MEN-PNU, MEN-PNU).   [return to index at top]  

  1. SIMULTANEOUS VACCINATION NOTATION.  As a convention to indicate the administration of separate vaccines to the same patient on the same day, in distinct sequential parenteral injections or oral/mucosal dosings (often described as "simultaneous vaccination"), the plus symbol surrounded by spaces ( + ) should separate abbreviations of the multiple vaccines administered.  For example, "At a clinic visit at 2 months of age, the patient received  DTPw-HIB + HBV + OPV + ROT".  Or, "In this study, one group received DTPa-HBV-POL + HIB + HAV + INFa, while another received DTPa-HIB + HAV-HBV + POLIPV + INFa".   [return to index at top]
       

  2. AMBIGUOUS AND ILLEGIBLE CONJUNCTIONS.  Strongly discouraged is the use of reverse (\), vertical (|), or forward slashes (/) to link the separate component antigens of a combination vaccine, or to denote simultaneous vaccination, or to distinguish the lyophilized component from the liquid component(s) of a combination vaccine.  Such conjunctions are ambiguous in meaning and provide poor visual resolution.  (Compare the visual distance at which the components of these two notations can be discerned: DTPa-HIB-HBV-POL and DTPa/HIB/HBV/POL.)  [return to index at top]   

  3. USER FLEXIBILITY.  Users may face circumstances in which more (or less) specificity is needed for an abbreviation.  In such cases, one or more subscripts may be added to (or removed from) a listed abbreviation.  Additional dashes or hyphens may be added to separate multiple specifers, at the user's discretion, according to guidelines for specifier dashes, above.  The intended meaning of such a modified abbreviation should be spelled out at first use of the abbreviation, or explained elsewhere in the document.  Examples follow: 
     

    • Conjugate used.  To identify a vaccine by the protein with which it is conjugated, the  PNUcn  abbreviation, for example, could be appended, as in  PNUcn-T, PNUcn-DPNUcn-OMPC,  and PNUcn-CRM197  or just   PNUcn-CRM .    [return to index at top]  

    • Serotypes and seed strains.  To identify the specific serotypes in a vaccine, their letter or number designations can be added to the abbreviation.  For example, the MENps  and  MENcn  abbreviations could become  MENps-ACYWMENcn-AC,  and  MENcn-B.  The live attenuated, cholera vaccine comprised of recombinant vector Salmonella typhi Ty21a strain from the Center for Vaccine Development (CVD103-HgR) could be abbreviated as CHOarvCVD103-HgROPV1  and OPV2  could designate the monovalent oral polio vaccines studied and used in the late 1950s and early 1960s for vaccines of type 1 and type 2, respectively.  However, "OPV3" would be ambiguous: it could be interpreted as a redundant abbreviation for OPV -- the current trivalent oral polio vaccine -- or as a representation of the former monovalent type 3 vaccine.  Thus, OPV3  should be accompanied at its first use in a document by an explanation of its intended meaning.   [return to index at top]  

    • Valency.  To identify a vaccine by its number of serotypes, serogroups, or component antigens, the quantity can be added to the subscript, as in  PNUps-23, PNUcn-7PNUcn-11DTPa-1, DTPa-2DTPa-3,  and DTPa-4  (the four latter DTPa vaccines use numbers to indicate the number of acellular antigens of pertussis toxin, pertactin, filamentous hemagglutinin, and/or fimbriae included in each vaccine).   [return to index at top]

        
    • Manufacturer.  To identify a vaccine by its producer or distributor, the manufacturer's abbreviation can be added as a subscript within parentheses, e.g., ANT(BPT), DTPa(WYE), DTPa(NAV), DTPa(AVP), HBV(GSK), HBV(MRK), INF(AVIR), INF(AVP), INF(MDV), INF(PDL), INF(WYE), PNUcn(AVP), PNUcn(MRK), PNUcn(WYE), PNUps(MRK), PNUps(WYE), RAB(CHIR), RAB(AVP)SMAvac(WYE), and TBEw(BAX).  No hyphen is needed when appending such a parenthesis to an existing subscript.   [return to index at top]

  4. ORDER OF MULTIPLE SUBSCRIPTS.  When various such specifiers are to be joined within an abbreviation's subscript, they should be listed in the following order, although intervening ones may be omitted:
      

    • First, the specifier for a MAJOR SUBCATEGORY of vaccine type, such as polysaccharide versus conjugate, acellular versus whole-cell antigens, inactivated versus live attenuated, etc.:  E.g., PNUcnDTPaINF 
        

    • Second, the specifier for a KEY COMPONENT contained in a vaccine, such as the protein conjugate:  E.g., PNUcn-CRMPNUcn-OMPC 
        

    • Third, the specifier for VALENCY to indicated the number of separate serotypes or antigens, etc.: E.g.,  PNUcn-CRM7  or  PNUcn-CRM-7PNUcn-OMPC7  or  PNUcn-OMPC-7PNUcn-T11  or  PNUcn-T-11DTPa-1, DTPa-2DTPa-3DTPa-4, INFa-3 

    • Fourth, the specifier to indicate the MANUFACTURER: E.g.,  PNUcn-CRM7(WYE)PNUcn-OMPC7(MRK), PNUcn-T11(AVP)DTPa-1(NAV), DTPa-2(AVP)DTPa-3(SBB), DTPa-4(WYE)INFa-3(AVIR)   [return to index at top]
        

  5. ABBREVIATION TABLE.  The following table lists the proposed main root abbreviations for vaccines against most target diseases, as well as some examples of various optional specifiers to distinguish among different vaccines for the same disease.  The more complex specifiers might be used in technical scientific publications, while simpler specifiers, if any, may suffice for general record-keeping in medical charts.    Columns 2 and 3 illustrate alternatives when subscripting is not available, either by reducing specifier font size, or by entering plain text when no formatting is possible.  Entries are listed alphabetically by the spelling of the abbreviation.

jump to:  A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - Y

[return to index at top]

1.  Preferred Abbreviation (subscripted specifiers) Abbreviation Alternatives 4.  Full vaccine name
2.  Reduced-font-size specifiers 3.  Unformattable text

ADE

-

-

Adenovirus vaccine, not otherwise specified

ADE4

ADE4

ADE4

Adenovirus vaccine, type 4, live, oral

ADE7

ADE7

ADE7

Adenovirus vaccine, type 7, live, oral

AFT

-

-

African trypanosomiasis (sleeping sickness, Trypanosoma brucei, T. brucei gambiense, T. brucei rhodesiense) vaccine

ALZ

-

-

Alzheimer's disease vaccine

AME

-

-

Amebiasis (Entamoeba histolytica) vaccine

AMT

-

-

American trypanosomiasis (Chagas' disease, Trypanosoma cruzi) vaccine

ANC

-

-

Ancylostoma duodenale (Old World hookworm) vaccine

ANT

-

-

Anthrax vaccine, not otherwise specified

ANTad

ANTad

ANTad

Anthrax vaccine, adsorbed

BAC

-

-

Bacterial vaccine, mixed stock, not otherwise specified

BAN

-

-

Bancroftian filariasis (Wuchereria bancrofti) vaccine

BCL

-

-

Bacillus species vaccine, not otherwise specified

BCG  *

-

-

Bacille Calmette-Guérin tuberculosis vaccine (see TUB)

BLA

-

-

Blastomyces dermatitidis (North American blastomycosis) vaccine

BOT

-

-

Botulism (Clostridium botulinum) toxoid vaccine, serogroup(s) not otherwise specified

BOTA

BOTA

BOTA

Botulism (Clostridium botulinum) serogroup A toxoid vaccine [Use subscripts B, C, D, etc., for other serogroups, accordingly.]

BOTABC , BOT3

BOTABC , BOT3

BOTABC , BOT3

Botulism (Clostridium botulinum) serogroups A, B, and C trivalent toxoid vaccine

BOTABCDE , BOT5

BOTABCDE , BOT5

BOTABCDE , BOT5

Botulism (Clostridium botulinum) serogroups A, B, C, D, and E pentavalent toxoid vaccine

BOTatx

BOTatx

BOTatx

Botulism (Clostridium botulinum) antitoxin

BRC

-

-

Brucellosis (Brucella abortus, B. canis, B. melitensis, B. suis) vaccine

BRM

-

-

Brugia malayi (Malayan filariasis, former genus: Wuchereria malayi) vaccine

BRT

-

-

Brugia timori (Timor) lymphatic filariasis vaccine

[return to alphabetical index at table top]

CAM

-

-

Campylobacter vaccine, not otherwise specified

CAMj

CAMj

CAMj

Campylobacter jejuni vaccine

CAMj-rvSAL

CAMj-rvSAL

CAMj-rvSAL

Campylobacter jejuni vaccine, recombinant Salmonella typhi vector

CAN

-

-

Candidiasis (Candida albicans, moniliasis) vaccine

CAN-KLE

-

-

Candida albicans, and Klebsiella pneumoniae vaccine

CCM

-

-

Coccidioidomycosis (Valley fever) (Coccidioides immitis) vaccine

CENav

CENav

CENav

Centruroides sculpturatus (bark scorpion) antivenin

CHA

-

-

Chancroid (Haemophilus ducreyi) vaccine

CHI

-

-

Chikungunya virus vaccine

CHO

-

-

Cholera vaccine, not otherwise specified

CHOa

CHOa

CHOa

Cholera vaccine, attenuated live (oral)

CHOiw

CHOiw

CHOiw

Cholera vaccine, inactivated whole cell

CHOiw-BS

CHOiw-BS

CHOiw-BS

Cholera vaccine, inactivated whole cell, B subunit

CHOcn-LPS

CHOcn-LPS

CHOcn-LPS

Cholera vaccine, lipopolysaccharide-toxin conjugate;

CHOo

CHOo

CHOo

Cholera, oral vaccine

CHOtxd

CHOtxd

CHOtxd

Cholera toxin/toxoid vaccine

CPN

-

-

Chlamydia pneumoniae vaccine

CPS

-

-

Chlamydia psittaci vaccine

CLD

-

-

Clostridium difficile vaccine

CLP

-

-

Clostridium perfringens (gas gangrene) vaccine [Use specifiers for Cl. oedematiens, Cl. septicum, or Cl. Sordellii vaccines]

CLWc

CLWc

CLWc

Clostridium welchii type C (Pigbel) toxoid vaccine

CMV

-

-

Cytomegalovirus vaccine

CMVigiv

CMVigiv

CMVigiv

Cytomegalovirus immune globulin, intravenous

COP

-

-

Colibacilosis porcina vaccine

CRI

-

-

Crimean-Congo hemorrhagic fever (hantavirus genus) vaccine (see HNT)

CROav

CROav

CROav

Crotalidae (rattlesnake) antivenin

CRC

-

-

Cryptococcosis (Cryptococcus neoformans) vaccine

CRS

-

-

Cryptosporidiosis (Cryptosporidium parvum, C. baileyi, C. muris) vaccine

CTR

-

-

Chlamydia trachomatis vaccine

[return to alphabetical index at table top]

DEN

-

-

Dengue fever (Dengue virus) vaccine

DIP

-

-

Diphtheria toxoid vaccine

DIPatx

DIPatx

DIPatx

Diphtheria antitoxin

DIP-TET-POL , DIP-TET-POLIPV

DIP-TET-POL , DIP-TET-POLIPV

DIP-TET-POL , DIP-TET-POLIPV

Diphtheria toxoid, and tetanus toxoid, and poliovirus inactivated vaccine

DT  *

-

-

Diphtheria toxoid, and tetanus toxoid, adsorbed, for pediatric use

DTP  *

-

-

Diphtheria toxoid, tetanus toxoid, and pertussis (antigens unspecified) vaccine

DTPa  *

DTPa  *

DTPa  *

Diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccine, for pediatric use

DrTPar

DrTPar

DrTPar

Diphtheria toxoid (reduced antigen quantity for adults), tetanus toxoid, and acellular pertussis (reduced antigen quantity for adults) vaccine, for adult use

DTP-HIB

-

-

Diphtheria toxoid, tetanus toxoid, pertussis (antigens unspecified), and Haemophilus influenzae type b conjugate vaccine

DTPa-HBV

DTPa-HBV

DTPa-HBV

Diphtheria toxoid, tetanus toxoid, acellular pertussis, and hepatitis B vaccine

DTPa-HBV-POL , DTPa-HBV-POLIPV

DTPa-HBV-POL , DTPa-HBV-POLIPV

DTPa-HBV-POL , DTPa-HBV-POLIPV 

Diphtheria toxoid, tetanus toxoid, acellular pertussis, hepatitis B, and poliovirus inactivated vaccine

DTPa-HIB

DTPa-HIB

DTPa-HIB

Diphtheria toxoid, tetanus toxoid, acellular pertussis, and Haemophilus influenzae type b conjugate vaccine

DTPa-HIB-HBV

DTPa-HIB-HBV

DTPa-HIB-HBV

Diphtheria toxoid, tetanus toxoid, acellular pertussis, Haemophilus influenzae type b conjugate, and hepatitis B vaccine

DTPa-HIB-HBV-POL , DTPa-HIB-HBV-POLIPV

DTPa-HIB-HBV-POL , DTPa-HIB-HBV-POLIPV

DTPa-HIB-HBV-POL , DTPa-HIB-HBV-POLIPV

Diphtheria toxoid, tetanus toxoid, acellular pertussis, Haemophilus influenzae type b conjugate, hepatitis B, and poliovirus inactivated vaccine

DTPa-HIB-HAV-HBV-POL , DTPa-HIB-HAV-HBV-POLIPV DTPa-HIB-HAV-HBV-POL , DTPa-HIB-HAV-HBV-POLIPV DTPa-HIB-HAV-HBV-POL , DTPa-HIB-HAV-HBV-POLIPV Diphtheria toxoid, tetanus toxoid, acellular pertussis, Haemophilus influenzae type b conjugate, hepatitis A, hepatitis B, and poliovirus inactivated vaccine

DTPa-HIB-POL , DTPa-HIB-POLIPV

DTPa-HIB-POL , DTPa-HIB-POLIPV

DTPa-HIB-POL , DTPa-HIB-POLIPV

Diphtheria toxoid, tetanus toxoid, acellular pertussis, Haemophilus influenzae type b conjugate, and poliovirus inactivated vaccine

DTPa-HIB-PNU

DTPa-HIB-PNU

DTPa-HIB-PNU

Diphtheria toxoid, tetanus toxoid, acellular pertussis, Haemophilus influenzae type b conjugate, and pneumococcal (Streptococcus pneumoniae) conjugate vaccine

DTPa-HIB-MEN-PNU

DTPa-HIB-MEN-PNU

DTPa-HIB-MEN-PNU

Diphtheria toxoid, tetanus toxoid, acellular pertussis, Haemophilus influenzae type b conjugate, meningococcal (Neisseria meningitidis) conjugate (serogroups unspecified), and pneumococcal (Streptococcus pneumoniae) conjugate vaccine

DTPa-POL , DTPa-POLIPV

DTPa-POL , DTPa-POLIPV

DTPa-POL , DTPa-POLIPV

Diphtheria toxoid, tetanus toxoid, acellular pertussis, and poliovirus inactivated vaccine

DTPa-MEN

DTPa-MEN

DTPa-MEN

Diphtheria toxoid, tetanus toxoid, acellular pertussis, and meningococcal (Neisseria meningitidis) conjugate (serogroups unspecified) vaccine

DTPa-PNU

DTPa-PNU

DTPa-PNU

Diphtheria toxoid, tetanus toxoid, acellular pertussis, and pneumococcal (Streptococcus pneumoniae) conjugate vaccine

DTPa-MEN-PNU

DTPa-MEN-PNU

DTPa-MEN-PNU

Diphtheria toxoid, tetanus toxoid, acellular pertussis, meningococcal (Neisseria meningitidis) conjugate (serogroups unspecified), and pneumococcal (Streptococcus pneumoniae) conjugate vaccine

DTPw

DTPw

DTPw

Diphtheria toxoid, tetanus toxoid, whole-cell pertussis vaccine

DTPw-HIB

DTPw-HIB

DTPw-HIB

Diphtheria, tetanus toxoids, whole-cell pertussis, and Haemophilus influenzae type b conjugate vaccine

DTPw-HIB-HBV

DTPw-HIB-HBV

DTPw-HIB-HBV

Diphtheria toxoid, tetanus toxoid, whole-cell pertussis, Haemophilus influenzae type b conjugate, and hepatitis B vaccine

[return to alphabetical index at table top]

EBO

-

-

Ebola virus (Filoviridae) vaccine, not otherwise specified

EBV

-

-

Epstein Barr virus (infectious mononucleosis, post-transplant lymphoproliferative disease, nasopharyngeal carcinoma, Hodgkin's disease, Burkitt's lymphoma) vaccine

ECO

-

-

Escherichia coli vaccine, not otherwise specified

ECOtxd-LPS

ECOtxd-LPS

ECOtxd-LPS

Escherichia coli (heat-labile toxin) vaccine, detoxified lipopolysaccharide

ECOEHEC

ECOEHEC

ECOEHEC

Escherichia coli (enterohemorrhagic Shiga toxin producing) vaccine

ECOETEC

ECOETEC

ECOETEC

Escherichia coli (enterotoxigenic, heat-labile toxin) vaccine

EEE

-

-

Eastern equine encephalitis vaccine, not otherwise specified

EEEiw

EEEiw

EEEiw

Eastern equine encephalitis vaccine, inactivated whole virus

EWE

-

-

Eastern & Western encephalomyelitis vaccine

FME

-

-

Frühsommer-meningoenzephalitis vaccine

GAS

-

-

Group A streptococcal disease (Streptococcus pyogenes) vaccine

GBS

-

-

Group B streptococcal disease (Streptococcus agalactiae) vaccine

GLA

-

-

Glanders (Actinobacillus mallei) vaccine

GON

-

-

Gonorrhea (Neisseria gonorrheae) vaccine

HAV

-

-

Hepatitis A vaccine

HAV-HBV

-

-

Hepatitis A and hepatitis B vaccine

HAV-TYD

-

-

Hepatitis A, and typhoid (Salmonella typhi) vaccine

HBV

-

-

Hepatitis B vaccine

HBVig

HBVig

HBVig

Hepatitis B immune globulin

HCV

-

-

Hepatitis C vaccine

HDV

-

-

Hepatitis D vaccine

HEL

-

-

Helicobacter pylori vaccine

HEV

-

-

Hepatitis E vaccine

HFR

-

-

Hemorrhagic fever with renal syndrome (Hantaan virus, hantavirus genus) vaccine (see HNT

HGV

-

-

Hepatitis G vaccine

HIB

-

-

Haemophilus influenzae type b vaccine, not otherwise specified

HIBcn

HIBcn

HIBcn

Haemophilus influenzae type b conjugate vaccine 

HIBps

HIBps

HIBps

Haemophilus influenzae type b polysaccharide vaccine

HIBHbOC , HIBcn-HbOC

HIBHbOC , HIBcn-HbOC

HIBHbOC ,

HIBcn-HbOC

Haemophilus influenzae type b conjugate vaccine (diphtheria CRM197 protein conjugate) [oligosaccharides conjugated to diphtheria CRM197 toxin protein]

HIBPRP-D , HIBcn-PRP-D

HIBPRP-D , HIBcn-PRP-D

HIBPRP-D , HIBcn-PRP-D 

Haemophilus influenzae type b conjugate vaccine (diphtheria toxoid conjugate) [polyribosylribitol phosphate polysaccharide conjugated to diphtheria toxoid]

HIBPRP-OMP , HIBcn-PRP-OMP

HIBPRP-OMP , HIBcn-PRP-OMP

HIBPRP-OMP , HIBcn-PRP-OMP

Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) [polyribosylribitol phosphate polysaccharide conjugated to a meningococcal outer membrane protein]

HIBPRP-T , HIBcn-PRP-T

HIBPRP-T , HIBcn-PRP-T

HIBPRP-T , HIBcn-PRP-T

Haemophilus influenzae type b conjugate vaccine (tetanus toxoid conjugate) [polyribosylribitol phosphate polysaccharide conjugated to tetanus toxoid]

HIB-HBV

-

-

Haemophilus influenzae type b conjugate, and hepatitis B vaccine

HIB-PNU-POL , HIB-PNU-POLIPV

HIB-PNU-POL , HIB-PNU-POLIPV

HIB-PNU-POL , HIB-PNU-POLIPV

Haemophilus influenzae type b conjugate, pneumococcal (Streptococcus pneumoniae) conjugate, and poliovirus inactivated vaccine

HIB-HBV-POL , HIB-HBV-POLIPV

HIB-HBV-POL , HIB-HBV-POLIPV

HIB-HBV-POL , HIB-HBV-POLIPV

Haemophilus influenzae type b conjugate, hepatitis B, and poliovirus inactivated vaccine

HIB-MEN

-

-

Haemophilus influenzae type b conjugate, and meningococcal (Neisseria meningitidis) conjugate (serogroups unspecified) vaccine

HIB-MEN-PNU

-

-

Haemophilus influenzae type b conjugate, meningococcal conjugate (serogroups unspecified), and pneumococcal (Streptococcus pneumoniae) conjugate vaccine

HIB-PNU

-

-

Haemophilus influenzae type b conjugate, and pneumococcal (Streptococcus pneumoniae) conjugate vaccine

HIN

-

-

Haemophilus influenzae nontypable strain(s) vaccine

HIS

-

-

Histoplasmosis (Histoplasma capsulatum) vaccine

HIV

-

-

AIDS (human immunodeficiency virus disease) vaccine, not otherwise specified (or type 1 inferred)

HIV1

HIV1

HIV1

AIDS (human immunodeficiency virus type 1 disease) vaccine, not otherwise specified

HIV2

HIV2

HIV2

AIDS (human immunodeficiency virus type2 disease) vaccine, not otherwise specified

HIVa

HIVa

HIVa

AIDS (human immunodeficiency virus disease) vaccine, attenuated live virus

HIVdna

HIVdna

HIVdna

AIDS (human immunodeficiency virus disease) vaccine, deoxyribose nucleic acid construct

HIVgp120-BB , HIV1-gp120-BB

HIVgp120-BB , HIV1-gp120-BB

HIVgp120-BB , HIV1-gp120-BB

AIDS (human immunodeficiency virus type 1 disease) vaccine, gp120 subunit protein, bivalent env subtypes B

HIVgp120-BE , HIV1-gp120-BE

HIVgp120-BE , HIV1-gp120-BE

HIVgp120-BE , HIV1-gp120-BE

AIDS (human immunodeficiency virus type 1 disease) vaccine, gp120 subunit protein, bivalent env subtypes B and E

HIVgp120-MN , HIV1-gp120-MN

HIVgp120-MN , HIV1-gp120-MN

HIVgp120-MN , HIV1-gp120-MN

AIDS (human immunodeficiency virus disease) vaccine, gp120 subunit protein, MN strain construct

HIVis , HIV1-is

HIVis , HIV1-is

HIVis , HIV1-is

AIDS (human immunodeficiency virus type 1 disease) vaccine, inactivated subvirion

HIViw , HIV1-iw

HIViw , HIV1-iw

HIViw , HIV1-iw

AIDS (human immunodeficiency virus type 1 disease) vaccine, inactivated whole virion

HIVrvAAV , HIV1-rvAAV

HIVrvAAV , HIV1-rvAAV

HIVrvAAV , HIV1-rvAAV

AIDS (human immunodeficiency virus type 1 disease) vaccine, recombinant vector adeno-associated virus

HIVrvBCG , HIV1-rvBCG

HIVrvBCG , HIV1-rvBCG

HIVrvBCG , HIV1-rvBCG

AIDS (human immunodeficiency virus type 1 disease) vaccine, recombinant vector Bacille-Calmette-Guérin

HIVrvVAC , HIV1-rvVAC

HIVrvVAC , HIV1-rvVAC

HIVrvVAC , HIV1-rvVAC

AIDS (human immunodeficiency virus type 1 disease) vaccine, recombinant vector vaccinia virus

HIVrvVAC-MVA , HIV1-rvVAC-MVA , HIVrvMVA

HIVrvVAC-MVA , HIV1-rvVAC-MVA , HIVrvMVA , HIVMVA

HIVrvVAC-MVA , HIV1-rvVAC-MVA , HIVrvMVA , HIVMVA 

AIDS (human immunodeficiency virus type 1 disease) vaccine, recombinant vector vaccinia virus, modified vaccinia Ankara (MVA) strain

HIVrv-vCP1452 , HIV1-rv-vCP1452

HIVrv-vCP1452 , HIV1-rv-vCP1452

HIVrv-vCP1452 , HIV1-rv-vCP1452

AIDS (human immunodeficiency virus type 1 disease) vaccine, recombinant vector canarypox strain vCP1452

HIVrvVSV , HIV1-rvVSV HIVrvVSV , HIV1-rvVSV

HIVrvVSV , HIV1-rvVSV

AIDS (human immunodeficiency virus type 1 disease) vaccine, recombinant vector vesicular stomatitis virus 

HNT

-

-

Hantavirus vaccine, not otherwise specified (see CRI, HFR, and SIN)

HPV

-

-

Human papillomavirus vaccine, not otherwise specified

HPVchVLP

HPVchVLP

HPVchVLP

Human papillomavirus vaccine, chimeric virus-like particle construct

HPVchVLP-16

HPVchVLP-16

HPVchVLP-16

Human papillomavirus vaccine, chimeric virus-like particle construct, monovalent type 16

HPVdna

HPVdna

HPVdna

Human papillomavirus vaccine, deoxyribosenucleic acid construct

HPVfp

HPVfp

HPVfp

Human papillomavirus vaccine, fusin protein construct

HPVhsp

HPVhsp

HPVhsp

Human papillomavirus vaccine, heat shock protein construct

HPVrvADE

HPVrvADE

HPVrvADE

Human papillomavirus vaccine, recombinant vector adenovirus

HPVrvBCG

HPVrvBCG

HPVrvBCG

Human papillomavirus vaccine, recombinant vector Bacille Calmette-Guérin

HPVrvMVA

HPVrvMVA

HPVrvMVA

Human papillomavirus vaccine, recombinant vector vaccinia virus, modified vaccinia Ankara (MVA) strain

HPVrvSAL

HPVrvSAL

HPVrvSAL

Human papillomavirus vaccine, recombinant vector Salmonella typhimurium

HPVrvVAC

HPVrvVAC

HPVrvVAC

Human papillomavirus vaccine, recombinant vector vaccinia virus

HPVrvVEE

HPVrvVEE

HPVrvVEE

Human papillomavirus vaccine, recombinant vector Venezuelan equine encephalitis virus

HPVVLP

HPVVLP

HPVVLP

Human papillomavirus vaccine, virus-like particle construct

HPVVLP-11-16-18

HPVVLP-11-16-18

HPVVLP-11-16-18

Human papillomavirus vaccine, virus-like particle construct, trivalent types 11, 16, 18

HSV

-

-

Herpes simplex virus vaccine

HSV1

HSV1

HSV1

Herpes simplex virus type 1 vaccine

HSV2

HSV2

HSV2

Herpes simplex virus type 2 vaccine

HSV1-2

HSV1-2

HSV1-2

Herpes simplex virus types 1, 2 vaccine

[return to alphabetical index at table top]

IDM

-

-

Insulin-dependent diabetes mellitus vaccine

IG , IGim  *

IG , IGim  *

IG , IGim  *

Immune globulin, intramuscular

IGiv  *

IGiv  *

IGiv  *

Immune globulin, intravenous

INF

-

-

Influenza vaccine, not otherwise specified

INFa

INFa

INFa

Influenza virus attenuated live vaccine

INFan

INFan

INFan

Influenza virus attenuated live vaccine, intranasal

INFi

INFi

INFi

Influenza virus inactivated vaccine

INFs

INFs

INFs

Influenza virus vaccine, split virion

INFs-AB3

INFs-AB3

INFs-AB3

Influenza virus vaccine, split virion, types A and B, trivalent

INFw

INFw

INFw

Influenza virus vaccine, whole virion

IPV  *

-

-

Poliovirus inactivated (injectable) vaccine [See POLIPV as equivalent alternative.]

JEN

-

-

Japanese encephalitis vaccine

JUN

-

-

Junín virus (Argentine hemorrhagic fever) vaccine, not otherwise specified

JUNC#1

JUNC#1

JUNC#1

Junín virus (Argentine hemorrhagic fever) vaccine, Candid #1 strain

KLE

-

-

Klebsiella vaccine

LAC

-

-

Lactobacillus acidophilus vaccine

LAS

-

-

Lassa fever (Lassa virus) vaccine

LATav

LATav

LATav

Latrodectus mactans (black-widow spider) antivenin

LCM

-

-

Lymphocytic choriomeningitis virus vaccine

LEG

-

-

Legionnaire's disease (Pontiac fever) (Legionella pneumophila) vaccine

LIS

-

-

Listeriosis (Listeria monocytogenes) vaccine, not otherwise specified

LISrv-SAL

LISrv-SAL

LISrv-SAL

Listeriosis (Listeria monocytogenes) vaccine, recombinant vector Salmonella typhimurium

LMPig

LMPig

LMPig

Lymphocyte immune globulin (anti-thymocyte globulin)

LPR

-

Leprosy (Hansen's disease) (Mycobacterium leprae) vaccine

LPT

-

-

Leptospirosis (Leptospira interrogans) vaccine, serovar(s) unspecified

LSC

-

-

Leishmaniasis, cutaneous, vaccine, not otherwise specified

LSCo

LSCo

LSCo

Leishmaniasis, cutaneous, Old World L. (Leishmania tropica complex: L. major, L. tropica, L. aethiopica, etc.) vaccine

LSCn

LSCn

LSCn

Leishmaniasis, cutaneous, New World L. (Leishmania mexicana complex: L. mexicana, L. amazonensis, etc.; L. braziliensis complex: L. braziliensis, L. guyanensis, L. panamensis, etc.) vaccine

LSV

-

-

leishmaniasis, visceral (Kala Azar) (Leishmania donovani complex: L. donovani, L. infantum, L. chagasi) vaccine

LYM

-

-

Lyme disease (Borreliosis; Borrelia sp.) vaccine, not otherwise specified

LYMe

LYMe

LYMe

Lyme disease (Borreliosis; Borrelia burgdorferi, B. garinii, B. afzelli) vaccine, European strains

LYMn

LYMn

LYMn

Lyme disease (Borreliosis; Borrelia burgdorferi sensu stricto) vaccine, North American strain

LYMospA

LYMospA

LYMospA

Lyme disease (Borreliosis; Borrelia sp.) vaccine, outer surface protein A

LYMospB

LYMospB

LYMospB

Lyme disease (Borreliosis; Borrelia sp.) vaccine, outer surface protein B

LYMospAC

LYMospAC

LYMospAC

Lyme disease (Borreliosis; Borrelia sp.) vaccine, outer surface proteins A and C

LYM-TBE

-

-

Lyme disease (Borreliosis; Borrelia sp. not otherwise specified) vaccine, and tick-borne encephalitis vaccine, not otherwise specified

[return to alphabetical index at table top]

MAL

-

-

Malaria vaccine, not otherwise specified

MALf

MALf

MALf

Malaria (Plasmodium falciparum) vaccine

MALf-MSP-1

MALf-MSP-1

MALf-MSP-1

Malaria (Plasmodium falciparum) vaccine, merozoite surface protein-1

MALf-cs

MALf-cs

MALf-cs

Malaria (Plasmodium falciparum) vaccine, circumsporozoite antigen

MALf-rvcs

MALf-rvcs

MALf-rvcs

Malaria (Plasmodium falciparum) vaccine, recombinant vector circumsporozoite antigen, vector unspecified

MALf-RTS,S

MALf-RTS,S

MALf-RTS,S

Malaria (Plasmodium falciparum) vaccine, RTS polypeptide chain of circumsporozoite protein fused to HBsAg and HBsAg polypeptide (S) alone

MALm

MALm

MALm

Malaria (Plasmodium malariae) vaccine

MALo

MALo

MALo

Malaria (Plasmodium ovale) vaccine

MALv

MALv

MALv

Malaria (Plasmodium vivax) vaccine

MAV

-

-

Mycobacterium avium vaccine

MBO

-

-

Mycobacterium bovis vaccine

MEA

-

-

Measles vaccine

MEA-RUB

-

-

Measles and rubella vaccine

MEA-SMA

-

-

Measles and smallpox vaccine

MEN

-

-

Meningococcal (Neisseria meningitidis) vaccine, not otherwise specified

MENcn

MENcn

MENcn

Meningococcal (Neisseria meningitidis) conjugate vaccine, serogroup(s) not otherwise specified

MENcn-AC

MENcn-AC

MENcn-AC

Meningococcal (Neisseria meningitidis) conjugate vaccine, serogroups A, C

MENcn-B

MENcn-B

MENcn-B

Meningococcal (Neisseria meningitidis) conjugate vaccine, serogroup B

MENcn-C

MENcn-C

MENcn-C

Meningococcal (Neisseria meningitidis) conjugate vaccine, serogroup C 

MENps

MENps

MENps

Meningococcal (Neisseria meningitidis) polysaccharide vaccine, serogroup(s) not otherwise specified

MENps-AC

MENps-AC

MENps-AC

Meningococcal (Neisseria meningitidis) polysaccharide vaccine, serogroups A, C

MENps-ACYW

MENps-ACYW

MENps-ACYW

Meningococcal (Neisseria meningitidis) polysaccharide vaccine, serogroups A, C, Y, W-135

MENps-B

MENps-B

MENps-B

Meningococcal (Neisseria meningitidis) polysaccharide vaccine, serogroup B

MEN-PNU

-

-

Meningococcal (Neisseria meningitidis) conjugate (serogroups unspecified), and pneumococcal (Streptococcus pneumoniae) conjugate vaccine, not otherwise specified

MICav

MICav

MICav

Micrurus fulvius (North American coral snake) antivenin

MLD

-

-

Melioidosis (Burkholderia [Pseudomonas] pseudomallei) vaccine

MLN

-

-

Melanoma vaccine

MMR  *

-

-

Measles, mumps, rubella vaccine

MMR-VAR

-

-

Measles, mumps, rubella, and varicella vaccine

MRV

-

-

Mixed respiratory vaccine

MRX

-

-

Moraxella catarrhalis vaccine

MUL

-

-

Multiple sclerosis vaccine

MUM

-

-

Mumps vaccine

MUM-RUB

-

-

Mumps and rubella vaccine

MVA

-

-

Mycobacterium vaccae vaccine

MYG

-

-

Mycoplasma genitalium vaccine

MYH

-

-

Mycoplasma hominis vaccine

MYP

-

-

Mycoplasma pneumonia (Mycoplasma pneumoniae) vaccine

NOR - - Norwalk virus (human Calicivirus) gastroenteritis vaccine
ONC - - Onchocerciasis (river blindness, Onchocerca volvulus) vaccine
OPV  * - - Poliovirus attenuated live oral trivalent vaccine.  [See POLOPV as equivalent alternative.]
OVA - - Ovarian cancer vaccine

[return to alphabetical index at table top]

PAC - - Paracoccidioidomycosis (South American blastomycosis, Paracoccidioides brasiliensis) vaccine
PAI - - Parainfluenza (paramyxovirus) vaccine
PER - - Pertussis (whooping cough) vaccine, antigens not otherwise specified
PERa PERa PERa Pertussis, acellular antigen(s), vaccine
PERw PERw PERw Pertussis, whole-cell antigens, vaccine
PLG - - Plague (Yersinia pestis) (la Peste) vaccine
PCP - - Pneumocystis carinii pneumonia vaccine
PNU - - Pneumococcal (Streptococcus pneumoniae) vaccine, not otherwise specified
PNUcn PNUcn PNUcn Pneumococcal (Streptococcus pneumoniae) conjugate vaccine, not otherwise specified
PNUcn-7 PNUcn-7 PNUcn-7 Pneumococcal (Streptococcus pneumoniae) conjugate vaccine, 7-valent
PNUcn-11 PNUcn-11 PNUcn-11 Pneumococcal (Streptococcus pneumoniae) conjugate vaccine, 11-valent
PNUcnCRM , PNUcnCRM197 PNUcnCRM , PNUcnCRM197 PNUcnCRM , PNUcnCRM197 Pneumococcal (Streptococcus pneumoniae) conjugate vaccine (mutant diphtheria toxin CRM197 protein conjugate)
PNUcnCRM-7 PNUcnCRM-7 PNUcnCRM-7 Pneumococcal (Streptococcus pneumoniae) conjugate vaccine, (mutant diphtheria toxin CRM197 protein conjugate), 7-valent
PNUcnOMPC PNUcnOMPC PNUcnOMPC Pneumococcal (Streptococcus pneumoniae) conjugate vaccine, (outer membrane protein conjugate)
PNUcnOMPC-7 PNUcnOMPC-7 PNUcnOMPC-7 Pneumococcal (Streptococcus pneumoniae) conjugate vaccine, (outer membrane protein conjugate), 7-valent
PNUcnT PNUcnT PNUcnT Pneumococcal (Streptococcus pneumoniae) conjugate vaccine, (tetanus toxoid conjugate)
PNUcnT-11 PNUcnT-11 PNUcnT-11 Pneumococcal (Streptococcus pneumoniae) conjugate vaccine, (tetanus toxoid conjugate), 11-valent
PNUps PNUps PNUps Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccine, not otherwise specified
PNUps-23 PNUps-23 PNUps-23 Pneumococcal (Streptococcus pneumoniae) polysaccharide, 23-valent vaccine
PNUPsaA PNUPsaA PNUPsaA Pneumococcal (Streptococcus pneumoniae) surface adhesin A vaccine
PNUPspA PNUPspA PNUPspA Pneumococcal (Streptococcus pneumoniae) surface protein A vaccine
PNUPspC PNUPspC PNUPspC Pneumococcal (Streptococcus pneumoniae) surface protein C vaccine
PNU-POL , PNU-POLIPV  PNU-POL , PNU-POLIPV PNU-POL , PNU-POLIPV pneumococcal (Streptococcus pneumoniae) conjugate, and poliovirus inactivated vaccine
POL - - Poliomyeltitis vaccine, not otherwise specified
POLIPV POLIPV POLIPV Poliovirus inactivated (injectable) vaccine [See IPV as grandfathered alternative.]
POLOPV POLOPV POLOPV Poliovirus attenuated live oral trivalent vaccine.  [See OPV as grandfathered alternative.]
PRO - - Prostate cancer vaccine
PSC - - Pseudomonas (Burkholderia) cepacia vaccine
PSU - - Pseudomonas aeruginosa vaccine
PTD - - Paratyphoid (Salmonella paratyphi) vaccine
PYT - - Pythiosis (Pythium insidiosum) vaccine

[return to alphabetical index at table top]

QF  * - - Q fever (Coxiella burnetii) vaccine
RAB - - Rabies vaccine, not otherwise specified
RABad RABad RABad Rabies vaccine, adsorbed
RABad-FRhL-2 RABad-FRhL-2 RABad-FRhL-2 Rabies vaccine, adsorbed, diploid fetal-rhesus-lung-2 cell line
RABDEV RABDEV RABDEV Rabies vaccine, duck embryo
RABFRhL-2 RABFRhL-2 RABFRhL-2 Rabies vaccine, diploid fetal-rhesus-lung-2 cell line
RABHDCV RABHDCV RABHDCV Rabies vaccine, human diploid cell culture
RABig RABig RABig Rabies immune globulin
RABPCEC RABPCEC RABPCEC Rabies vaccine, purified chick embryo cell culture
RHA - - Rheumatoid arthritis (therapeutic) vaccine
RHOig RHOig RHOig Rho (D) disease immune globulin (human)
RHOigiv RHOigiv RHOigiv Rho (D) disease immune globulin (human), intravenous
RHF - - Rheumatic fever vaccine
RMS - - Rocky Mountain spotted fever (Rickettsia rickettsii) vaccine
ROT - - Rotavirus disease vaccine, not otherwise specified
ROTrr ROTrr ROTrr Rotavirus vaccine, rhesus reassortant
RSV - - Respiratory syncytial virus disease vaccine
RSVigiv RSVigiv RSVigiv Respiratory syncytial virus disease immune globulin, intravenous
RSVmab RSVmab RSVmab Respiratory syncytial virus disease monoclonal antibody (palivizumab)
RUB - - Rubella vaccine
RVF - - Rift Valley fever vaccine, not otherwise specified
RVFi RVFi RVFi Rift Valley fever vaccine, inactivated

[return to alphabetical index at table top]

SAL - - Salmonellosis (Salmonella typhimurium) vaccine, serotype(s) not otherwise specified
SCH - - Schistosomiasis (Bilharziasis, Schistosoma sp.) vaccine, not otherwise specified
SCHh SCHh SCHh Schistosomiasis (Bilharziasis, Schistosoma haematobium) vaccine
SCHic SCHic SCHic Schistosomiasis (Bilharziasis, Schistosoma intercalatum) vaccine
SCHj SCHj SCHj Schistosomiasis (Bilharziasis, Schistosoma japonicum) vaccine
SCHma SCHma SCHma Schistosomiasis (Bilharziasis, Schistosoma mansoni) vaccine
SCHme SCHme SCHme Schistosomiasis (Bilharziasis, Schistosoma mekongi) vaccine
SHI - - Shigellosis (Shigella sp.) vaccine, not otherwise specified
SHId SHId SHId Shigellosis (Shigella dysenteriae) vaccine
SHIf SHIf SHIf Shigellosis (Shigella flexneri) vaccine
SHIs SHIs SHIs Shigellosis (Shigella sonnei) vaccine
SIN - - Sin nombre virus (hantavirus genus) disease vaccine (see HNT)
SIV - - Simian immunodeficiency virus disease vaccine, not otherwise specified
SMA - - Smallpox vaccine, not otherwise specified
SMAvac SMAvac SMAvac Smallpox (vaccinia virus) vaccine
SMAvac-cl SMAvac-cl SMAvac-cl Smallpox (vaccinia virus) vaccine, calf lymph type
SMAvac-tc SMAvac-tc SMAvac-tc Smallpox (vaccinia virus) vaccine, tissue culture type
STA - - Staphylococcus vaccine, not otherwise specified
STAaur STAaur STAaur Staphylococcus aureus vaccine
STAaur-5CPS-cnPSUeA STAaur-5CPS-cnPSUeA STAaur-5CPS-cnPSUeA Staphylococcus aureus vaccine, Type 5 capsular polysaccharide conjugated to Pseudomonas aeruginosa recombinant exoprotein A
STASPL STASPL STASPL Staphylococcus vaccine, bacteriophage lysate
SYP - - Syphilis (Treponema pallidum) vaccine
TBE - - Tick-borne encephalitis vaccine, not otherwise specified
TBEe TBEe TBEe Tick-borne encephalitis, eastern subtype (Far eastern encephalitis, Russian spring-summer e., Taiga e.) vaccine
TBEc TBEc TBEc Tick-borne encephalitis, central subtype (Central and Western European encephalitis) vaccine
Td  * - - Tetanus toxoid, and diphtheria toxoid (reduced antigen quantity for adults) vaccine, for adult use
TETig TETig TETig Tetanus immune globulin
TOX - - Toxoplasmosis (Toxoplasma gondii) vaccine
TPL - - Typhus, louse-borne (Rickettsiae prowazekii) vaccine
TPM - - Typhus, murine (Rickettsiae typhi) vaccine
TPS - - Typhus, scrub (Orientia tsutsugamushi, formerly Rickettsiae tsutsugamushi) vaccine
TT  * - - Tetanus (Clostridium tetani) toxoid vaccine
TUB - - Tuberculosis (Mycobacterium tuberculosis) vaccine, not BCG
TUL - - Tularemia (Francisella tularensis) vaccine
TYD - - Typhoid (Salmonella typhi) vaccine, not otherwise specified
TYDa TYDa TYDa Typhoid (Salmonella typhi) vaccine, attenuated live (oral Ty21a strain)
TYDAKD TYDAKD TYDAKD Typhoid (Salmonella typhi) vaccine, acetone-killed and dried (U.S. military)
TYDHP TYDHP TYDHP Typhoid (Salmonella typhi) vaccine, heat and phenol inactivated, dried
TYDVi TYDVi TYDVi Typhoid (Salmonella typhi) vaccine, Vi capsular polysaccharide
TYD-PTDTAB TYD-PTDTAB TYD-PTDTAB Typhoid (Salmonella typhi) and paratyphoid (Salmonella paratyphi) polyvalent (S. Schottmuelleri) aqueous vaccine

[return to alphabetical index at table top]

URE - - Ureaplasma urealyticum vaccine
VACig VACig VACig Vaccinia virus (smallpox vaccine) immune globulin [for smallpox vaccine, see SMA]
VAR - - Varicella (chickenpox) (varicella zoster) vaccine
VARig VARig VARig Varicella-zoster immune globulin
VEE - - Venezuelan equine encephalitis vaccine, not otherwise specified
VEEa-TC-83 VEEa-TC-83 VEEa-TC-83 Venezuelan equine encephalitis vaccine, attenuated live, TC-83 designation
VEEi-C-84 VEEi-C-84 VEEi-C-84 Venezuelan equine encephalitis vaccine, inactivated, C-84 designation
WEE - - Western equine encephalitis vaccine
YEL - - Yellow fever vaccine
* Abbreviation not in conformance with naming format, but adopted into VISI under "grandfathering" principle (3.)

  [return to index at top]

Resource links:


Comments and suggestions are welcome, particularly concerning past, existing, or future vaccines missing from the table, and should be communicated to visi@cdc.gov.

Return to top of page above

Return to top of abbreviations table above

VISI application guidelines and prototypes

VISI manufacturer abbreviations

VISI homepage

Top of page


National Immunization Program (NIP)
NIP Home | Contact Us | Help | Glossary | About | Accessibility

                          This page last modified on November 12, 2003

   

Department of Health and Human Services
Centers for Disease Control and Prevention
CDC Home
  |  CDC Search  |  CDC Health Topics A-Z